R24
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.530
- TNFA_SIGNALING_VIA_NFKB+0.400
- APICAL_SURFACE+0.360
- HYPOXIA+0.330
- KRAS_SIGNALING_DN+0.330
- WNT_BETA_CATENIN_SIGNALING+0.330
- COAGULATION+0.310
- MYOGENESIS+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- UV_RESPONSE_UP+0.250
Top 10 suppressed
- PROTEIN_SECRETION-0.530
- G2M_CHECKPOINT-0.350
- PI3K_AKT_MTOR_SIGNALING-0.350
- ANDROGEN_RESPONSE-0.310
- E2F_TARGETS-0.290
- MITOTIC_SPINDLE-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.290
- DNA_REPAIR-0.250
- UV_RESPONSE_DN-0.250
- MTORC1_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R236 | — | — | 0.863 |
| 2 | TCGA-85-A4JC-01A-11R-A24Z-07 | — | cohortSQ1 | 0.849 |
| 3 | SRR493947 | — | cohortA1 | 0.842 |
| 4 | BS_983Z6CA6 | ATRT | — | 0.812 |
| 5 | 82992 | EPN | Supratentorial EPN | 0.811 |
| 6 | BS_5JM573JC | Ganglioglioma | — | 0.797 |
| 7 | TCGA-B6-A40B-01A-11R-A239-07 | — | B | 0.797 |
| 8 | 16ab68fd-4948-4cd5-b5d8-1b2e8a1fd3cb | — | — | 0.794 |
| 9 | TCGA-B6-A401-01A-11R-A239-07 | — | B | 0.793 |
| 10 | SJEPD001517_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |